Agilent Technologies makes analytical instruments, consumables, software, and services used by labs across life sciences, pharma, diagnostics, chemicals, food safety, and environmental testing. Its flagship products are liquid chromatography (LC) and LC mass spectrometry (LCMS) systems, which separate and identify molecules in liquid mixtures and are workhorses in pharma and biotech QA/QC and R&D. Agilent also claims to be the world's leading maker of gas chromatography (GC) instruments, widely used in chemicals, food safety, environmental testing, and forensics. Agilent's business model combines instrument sales — capital equipment purchases driven by new lab builds and fleet replacement cycles — with a large recurring revenue base of services, consumables (columns, reagents), and software tied to its installed instrument base. Each new instrument placement creates an ongoing revenue stream, and Agilent's CrossLab segment is the primary vehicle for capturing this. Beyond instruments, Agilent operates a specialty contract development and manufacturing organization (CDMO) business through its NASD and BioVectra units, which manufacture complex drug ingredients like oligonucleotides and GLP-1 peptides for pharma customers under contract. Agilent operates through three segments: Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets. Growth priorities include an ongoing LC/GC instrument replacement cycle, CDMO capacity expansion, and PFAS testing, where Agilent holds a leading position in a rapidly growing regulatory-driven market.